http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 04:45:07 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+DINO+CTMX+ABUS+RYAM+EWY+AMPY+PBF+ODD+BNO/26114121.html <p>Increasing unusual option volume: DINO CTMX ABUS RYAM EWY AMPY PBF ODD BNO</p> http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+DINO+CTMX+ABUS+RYAM+EWY+AMPY+PBF+ODD+BNO/26114121.html Thu, 05 Mar 2026 04:45:07 -0500 ABUS http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+ABUS+GLNG+COUR+EWY+BGS+BOX+TECK+WTI+EXAS+FSLY+ROST+FLNG+LASR/26108449.html <p>Increasing unusual option volume: ABUS GLNG COUR EWY BGS BOX TECK WTI EXAS FSLY ROST FLNG LASR</p> http://www.streetinsider.com/Options/Increasing+unusual+option+volume%3A+ABUS+GLNG+COUR+EWY+BGS+BOX+TECK+WTI+EXAS+FSLY+ROST+FLNG+LASR/26108449.html Wed, 04 Mar 2026 09:52:34 -0500 ABUS http://www.streetinsider.com/Analyst+Comments/Chardan+Reiterates+Buy+Rating+on+Arbutus+Biopharma+%28ABUS%29+Following+Moderna+Settlement/26108279.html <p>Chardan analyst Keay Kakae reiterated a Buy rating and $5.00 price target on Arbutus Biopharma (NASDAQ: ABUS) after a global settlement was reached with Moderna between Arbutus and Genevant with $950 million upfront, and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.</p><p>"Under the terms of the intellectual property licensed by Arbutus to Genevant, infringement by any third parties of Arbutus’s patents, entitles Arbutus to receive, after deduction of litigation costs, 20% of the proceeds received. We estimate that the legal fees in a case of this length, and settlement size are likely substantial, likely http://www.streetinsider.com/Analyst+Comments/Chardan+Reiterates+Buy+Rating+on+Arbutus+Biopharma+%28ABUS%29+Following+Moderna+Settlement/26108279.html Wed, 04 Mar 2026 09:21:22 -0500 ABUS http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Special+Reports/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html <p><strong>After-hours movers:</strong></p><p><strong>Moderna</strong> (NASDAQ: MRNA) rose 10%, <strong>Roivant Sciences</strong> (NASDAQ: ROIV) rose 6% and <strong>Arbutus Biopharma</strong> (NASDAQ: ABUS) rose 15% after a $2.25 billion global settlement to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax</p><p><strong>CrowdStrike </strong>(NASDAQ: CRWD) fell 1.25% after in-line quarterly results and guidance. Total revenue was $1.31 billion, a 23% increase, compared to $1.06 billion in the fourth quarter of fiscal 2025. </p><p><strong>GitLab Inc</strong> (NASDAQ: GTLB) fell 3% after guidance disappointed investors. GitLab sees FY2027 EPS of $0.76-$0.80, versus the consensus of http://www.streetinsider.com/Hot+List/After-hours+movers%3A+Moderna%2C+CrowdStrike%2C+Ross+Stores%2C+Box+and+more/26102138.html Tue, 03 Mar 2026 16:33:03 -0500 ABUS BGS BOX CRWD GTLB MRNA ROIV ROST http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Mar+03/26101732.html si-local-file:///var/storage/secattach/20260303/26101732.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Mar+03/26101732.html Tue, 03 Mar 2026 16:21:00 -0500 ABUS O.01268577 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Mar+03/26101732.html si-local-file:///var/storage/secattach/20260303/26101732.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Arbutus+Biopharma+Corp++++For%3A+Mar+03/26101732.html Tue, 03 Mar 2026 16:21:00 -0500 ABUS O.01268577 http://www.streetinsider.com/Litigation/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html <p>Roivant Sciences (NASDAQ: ROIV) announced that its subsidiary Genevant Sciences and partner Arbutus Biopharma Corporation (NASDAQ: ABUS) have reached a $2.25 billion settlement with Moderna Inc. to resolve patent infringement litigation related to lipid nanoparticle (LNP) delivery technology used in Moderna's COVID-19 vaccines.</p><p>Under the settlement terms, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion payment is contingent upon a favorable appellate ruling regarding whether Section 1498 of federal law bars the patent claims against Moderna, except for doses provided to U.S. government employees.</p><p>The settlement requires Moderna to accept a court judgment of patent infringement and http://www.streetinsider.com/Litigation/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html Tue, 03 Mar 2026 16:16:20 -0500 ABUS ROIV http://www.streetinsider.com/Litigation/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html <p>Roivant Sciences (NASDAQ: ROIV) announced that its subsidiary Genevant Sciences and partner Arbutus Biopharma Corporation (NASDAQ: ABUS) have reached a $2.25 billion settlement with Moderna Inc. to resolve patent infringement litigation related to lipid nanoparticle (LNP) delivery technology used in Moderna's COVID-19 vaccines.</p><p>Under the settlement terms, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion payment is contingent upon a favorable appellate ruling regarding whether Section 1498 of federal law bars the patent claims against Moderna, except for doses provided to U.S. government employees.</p><p>The settlement requires Moderna to accept a court judgment of patent infringement and http://www.streetinsider.com/Litigation/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html Tue, 03 Mar 2026 16:16:20 -0500 ABUS ROIV http://www.streetinsider.com/Corporate+News/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html <p>Roivant Sciences (NASDAQ: ROIV) announced that its subsidiary Genevant Sciences and partner Arbutus Biopharma Corporation (NASDAQ: ABUS) have reached a $2.25 billion settlement with Moderna Inc. to resolve patent infringement litigation related to lipid nanoparticle (LNP) delivery technology used in Moderna's COVID-19 vaccines.</p><p>Under the settlement terms, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion payment is contingent upon a favorable appellate ruling regarding whether Section 1498 of federal law bars the patent claims against Moderna, except for doses provided to U.S. government employees.</p><p>The settlement requires Moderna to accept a court judgment of patent infringement and http://www.streetinsider.com/Corporate+News/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html Tue, 03 Mar 2026 16:16:20 -0500 ABUS ROIV http://www.streetinsider.com/Corporate+News/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html <p>Roivant Sciences (NASDAQ: ROIV) announced that its subsidiary Genevant Sciences and partner Arbutus Biopharma Corporation (NASDAQ: ABUS) have reached a $2.25 billion settlement with Moderna Inc. to resolve patent infringement litigation related to lipid nanoparticle (LNP) delivery technology used in Moderna's COVID-19 vaccines.</p><p>Under the settlement terms, Moderna will pay $950 million upfront in July 2026. An additional $1.3 billion payment is contingent upon a favorable appellate ruling regarding whether Section 1498 of federal law bars the patent claims against Moderna, except for doses provided to U.S. government employees.</p><p>The settlement requires Moderna to accept a court judgment of patent infringement and http://www.streetinsider.com/Corporate+News/Roivant%27s+Genevant+and+Arbutus+reach+%242.25+billion+settlement+with+Moderna/26101574.html Tue, 03 Mar 2026 16:16:20 -0500 ABUS ROIV